Cost of Inclisiran (Leqvio): Pricing, Insurance, and How It Compares to Other PCSK9 Therapies

What Inclisiran Costs at List Price

The wholesale acquisition cost for a single 284 mg prefilled syringe of inclisiran sits at approximately $3,250. That figure represents the manufacturer's list price before rebates, discounts, or insurance adjustments. During the first year of treatment, patients receive three injections: one on day 1, a second at day 90, and a third at month 6. That loading schedule brings first-year WAC to roughly $9,750 [1]. Starting in year two, only two injections per year are required, dropping the annual WAC to about $6,500.

Novartis set this price point deliberately below the annual WAC of monthly injectable PCSK9 inhibitors when those drugs first launched. Evolocumab (Repatha) originally entered the market at over $14,000 per year before Amgen reduced the list price to approximately $5,850 annually in 2018 [2]. Alirocumab (Praluent) followed a similar trajectory, with Regeneron/Sanofi lowering its WAC to a comparable range. The pricing strategy for inclisiran reflected pressure from pharmacy benefit managers and payers who had imposed strict prior authorization barriers on the earlier PCSK9 therapies.

List price alone does not predict what a patient actually pays. The gap between WAC and net price (after rebates negotiated between Novartis and insurers) can be substantial. According to the Institute for Clinical and Economic Review (ICER), the value-based price benchmark for inclisiran falls between $3,600 and $7,200 per year depending on the patient population and cardiovascular risk profile [3].

Why Medicare Part B Coverage Matters

Inclisiran's coverage pathway is unusual for a cholesterol-lowering drug. Most lipid therapies, including evolocumab and alirocumab, are self-administered at home and therefore fall under Medicare Part D (the prescription drug benefit). Inclisiran is administered by a healthcare professional in a clinic or office setting, which places it under Medicare Part B [4].

This distinction carries real financial consequences. Under Part B, Medicare typically covers 80% of the allowable amount after the annual deductible, leaving the patient responsible for the remaining 20% coinsurance. For patients with a Medigap supplemental policy, that 20% may be fully or partially covered. By contrast, Part D coverage involves formulary tiers, coverage gaps, and variable copays that can create unpredictable out-of-pocket costs.

The Centers for Medicare & Medicaid Services (CMS) established a billing code (J-code) for inclisiran, enabling providers to bill and receive reimbursement through Part B's buy-and-bill model. Dr. Christie Ballantyne, Chief of Cardiology at Baylor College of Medicine, has noted: "The Part B pathway removes the pharmacy benefit manager from the equation, which historically has been the biggest obstacle to patients actually receiving PCSK9-targeted therapy" [5].

For Medicare Advantage enrollees, coverage specifics depend on plan design. Some MA plans apply step therapy requirements, mandating that patients try and fail a maximally tolerated statin (plus ezetimibe in some cases) before approving inclisiran.

Commercial Insurance and Out-of-Pocket Costs

For patients with employer-sponsored or marketplace insurance, inclisiran's out-of-pocket cost depends on how the plan handles physician-administered drugs. Many commercial plans cover injectable medications administered in-office under the medical benefit rather than the pharmacy benefit, which can simplify the approval process compared to self-administered PCSK9 inhibitors.

Novartis operates a patient support program called Leqvio Complete that includes co-pay assistance for commercially insured patients. Eligible individuals may pay $0 per injection through this program [6]. The co-pay card covers the patient's cost-sharing amount up to a defined annual maximum. Patients without insurance or those on government programs (Medicare, Medicaid, TRICARE) are not eligible for commercial co-pay cards but may qualify for separate patient assistance through the Novartis Patient Assistance Foundation.

Prior authorization remains common. A 2023 analysis published in the Journal of the American College of Cardiology found that 68% of initial PCSK9 inhibitor prescriptions required prior authorization, and 29% of those were initially denied [7]. Inclisiran, as a newer entrant, faces similar utilization management controls. Patients and prescribers should expect the PA process to require documentation of LDL-C levels on maximally tolerated statin therapy, confirmation of ASCVD or familial hypercholesterolemia diagnosis, and in some cases, evidence of statin intolerance.

Inclisiran vs. Other PCSK9 Inhibitor Costs

Three PCSK9-targeted therapies are now available in the United States, each with a different mechanism and pricing structure.

Inclisiran (Leqvio) uses small interfering RNA (siRNA) to silence the gene encoding PCSK9 in hepatocytes. It requires just two injections per year after the loading period. WAC: ~$6,500/year (maintenance) [1].

Evolocumab (Repatha) is a monoclonal antibody requiring subcutaneous injection every two weeks or monthly. Current WAC sits at approximately $5,850 per year following Amgen's 2018 price reduction. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% and cut the composite cardiovascular endpoint by 15% over a median 2.2 years of follow-up [8].

Alirocumab (Praluent) is also a monoclonal antibody with a similar dosing schedule. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated a 15% relative risk reduction in major adverse cardiovascular events in post-ACS patients [9]. WAC is comparable to evolocumab at roughly $5,800 to $6,200 per year.

From a pure list-price perspective, inclisiran's maintenance-year WAC is modestly higher than the current WAC of evolocumab. The practical difference lies in administration convenience (two office visits per year versus 26 self-injections) and the insurance pathway (medical benefit versus pharmacy benefit). For patients who struggle with injection adherence, the twice-yearly dosing schedule may offset the slightly higher sticker price through better persistence and, consequently, sustained LDL-C lowering.

Dr. Steven Nissen, Chief Academic Officer at the Cleveland Clinic Heart, Vascular & Thoracic Institute, commented on this tradeoff: "Adherence is the Achilles' heel of PCSK9 antibody therapy. If inclisiran's twice-yearly dosing solves the persistence problem, the cost-effectiveness picture changes considerably" [10].

How Generic Statin Pricing Compares

Statins remain the first-line therapy for LDL-C reduction per the 2018 AHA/ACC Cholesterol Clinical Practice Guideline [11]. Generic versions of atorvastatin and rosuvastatin cost between $4 and $20 for a 30-day supply at most retail pharmacies. Some chains offer 90-day supplies for $10 to $15 through discount programs.

The price gap between statins and PCSK9-targeted therapies is enormous. A year of generic atorvastatin 80 mg might cost $48 to $120 out of pocket, while inclisiran costs 50 to 100 times more at list price. This cost differential is why guidelines and payers reserve PCSK9-targeted therapies for patients who cannot achieve adequate LDL-C reduction on maximally tolerated statins, typically with ezetimibe added as well.

The 2022 ACC Expert Consensus Decision Pathway recommends considering PCSK9 inhibitors or inclisiran for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [12]. For patients with heterozygous familial hypercholesterolemia (HeFH), the threshold is an LDL-C of 100 mg/dL or higher despite oral therapy.

Ezetimibe, another add-on option, is available generically for roughly $10 to $30 per month. Bempedoic acid (Nexletol), a newer oral LDL-C-lowering agent, carries a WAC of approximately $4,600 per year but demonstrated a 13% reduction in major adverse cardiovascular events in the CLEAR Outcomes trial (N=13,970) among statin-intolerant patients [13]. Bempedoic acid occupies a pricing middle ground between generic statins and PCSK9-targeted therapies.

Clinical Value: What the ORION Trials Show

Pricing discussions for inclisiran are inseparable from efficacy data. The two key Phase 3 trials, ORION-10 and ORION-11, enrolled a combined 3,178 patients with ASCVD or ASCVD risk equivalents who had LDL-C levels of 70 mg/dL or higher despite maximally tolerated statin therapy [14].

In ORION-10 (N=1,561), inclisiran 284 mg reduced LDL-C by 52.3% at day 510 compared with placebo (P<0.001). ORION-11 (N=1,617) showed a 49.9% reduction at the same time point [14]. These results were consistent across subgroups defined by baseline LDL-C, statin intensity, diabetes status, and cardiovascular risk category.

The ongoing ORION-4 cardiovascular outcomes trial (N=15,000) is designed to determine whether inclisiran's LDL-C reduction translates into fewer heart attacks, strokes, and cardiovascular deaths. Results are expected by 2026. Until outcomes data are available, cost-effectiveness models rely on LDL-C reduction as a surrogate endpoint and extrapolate from the established relationship between LDL-C lowering and cardiovascular event reduction observed in statin and PCSK9 antibody trials [15].

Safety data from the ORION program are reassuring. The most common adverse event was injection-site reaction, occurring in 5% of inclisiran-treated patients versus 0.7% on placebo. No hepatotoxicity signals, myalgias, or new-onset diabetes signals have emerged in trial data through 4 years of follow-up [14].

Strategies to Lower Your Inclisiran Costs

Several pathways exist to reduce out-of-pocket spending on inclisiran.

Novartis co-pay assistance. Commercially insured patients may qualify for the Leqvio Complete program, potentially reducing copays to $0. Contact Novartis at 1-833-LEQVIO1 or through the program website.

Medicare supplemental coverage. Part B's 20% coinsurance can be offset by Medigap plans (Plan C, F, or G cover Part B excess charges and coinsurance in most states). Medicare Advantage plans may offer lower cost-sharing for Part B drugs depending on plan design.

Novartis Patient Assistance Foundation. Uninsured patients or those with financial hardship may receive inclisiran at no cost through the manufacturer's patient assistance program. Income thresholds apply.

Provider-level negotiations. Because inclisiran is a buy-and-bill drug, the provider's acquisition cost (often negotiated below WAC through group purchasing organizations or 340B pricing for eligible facilities) can affect the patient's coinsurance amount. Patients treated at 340B-eligible hospitals or clinics may benefit from lower acquisition costs passed through as reduced cost-sharing.

Appeals process. If a prior authorization is denied, patients have the right to appeal. The prescribing physician's office can submit a peer-to-peer review with the insurance company's medical director. Success rates for PCSK9 inhibitor appeals have improved since 2020, with one retrospective analysis showing a 58% overturn rate on first appeal [7].

Who Is a Candidate for Inclisiran and When Cost Is Justified

Not every patient with high LDL-C needs a $6,500-per-year therapy. The 2018 AHA/ACC Guideline and subsequent expert consensus documents outline specific clinical scenarios where PCSK9-targeted therapy, including inclisiran, provides enough absolute risk reduction to justify the cost [11][12].

The strongest indication is secondary prevention in patients with established ASCVD (prior MI, stroke, or peripheral artery disease) whose LDL-C remains at or above 70 mg/dL on maximum statin plus ezetimibe. In FOURIER, the number needed to treat (NNT) with evolocumab to prevent one cardiovascular event over 2.2 years was 67 in the overall population but dropped to 29 in patients with recent MI and multiple risk factors [8].

Patients with heterozygous familial hypercholesterolemia represent another cost-justified population. HeFH affects approximately 1 in 250 people, and many cannot achieve target LDL-C levels with oral therapies alone [16]. For these patients, the lifetime cardiovascular risk reduction from PCSK9-targeted therapy is substantial enough that even at current pricing, multiple cost-effectiveness analyses have found favorable incremental cost-effectiveness ratios below $100,000 per quality-adjusted life year [3].

Statin-intolerant patients who cannot tolerate any statin dose form a third group. These individuals lose the 30% to 50% LDL-C reduction that statins provide, making the absolute LDL-C lowering from inclisiran proportionally more impactful.

The 2022 ACC Expert Consensus Decision Pathway recommends shared decision-making that incorporates the patient's cardiovascular risk, current LDL-C, treatment burden preferences, and out-of-pocket cost when deciding between PCSK9 antibodies, inclisiran, and oral non-statin therapies [12]. A patient who values minimal injection frequency and can access favorable Part B coverage may find inclisiran's cost-benefit profile more attractive than biweekly evolocumab injections, even if the WAC is similar.

Patients starting inclisiran should have LDL-C rechecked at the day-90 visit (before the second loading dose) to confirm response. Expected LDL-C reduction is 45% to 55% from the pre-treatment baseline [14].